WAM
FLNA

Wakefield Asset Management’s Filana Therapeutics FLNA Stock Holding History

Wakefield Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-286
Closed – – 199
2019
Q2 		$0 Hold
286
– – ﹤0.01% 226
2019
Q1 		$0 Hold
286
– – ﹤0.01% 249
2018
Q4 		$0 Hold
286
– – ﹤0.01% 229
2018
Q3 		$0 Buy
+286
New +$435 ﹤0.01% 167

Other funds holding FLNA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wakefield Asset Management's FLNA Position: Q3 2019 in Review

Wakefield Asset Management sold out of Filana Therapeutics (FLNA) in Q3 2019, closing a stake of 286 shares.

Wakefield Asset Management first reported a position in FLNA in Q3 2018 and held it in 4 quarters. The position peaked at $0 in Q2 2019. 23 funds tracked by Wall St. Rank hold FLNA as of Q3 2019.

  • Wakefield Asset Management reported no remaining Filana Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Wakefield Asset Management sold 286 Filana Therapeutics shares in Q3 2019.
  • Wakefield Asset Management first reported a position in Filana Therapeutics in Q3 2018 and held it in 4 quarters.
  • Wakefield Asset Management's Filana Therapeutics position peaked at $0 in Q2 2019.
  • 23 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2019.

Based on Wakefield Asset Management's 13F filing for Q3 2019, filed 25 Oct 2019.